中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

40 records (took 0.046 seconds)

    Peptide vaccines for cancers expressing tumor-associated antigens
    21.
    发明授权
    Peptide vaccines for cancers expressing tumor-associated antigens 有权
    表达肿瘤相关抗原的癌症疫苗

    公开(公告)号：US09067973B2

    公开(公告)日：2015-06-30

    申请号：US14079144

    申请日：2013-11-13

    Applicant: ONCOTHERAPY SCIENCE, INC.

    Inventor： Takuya Tsunoda ,  Ryuji Ohsawa

    IPC: A61K38/00 ,  C07K4/12 ,  A61K31/7088 ,  C07K14/47 ,  C07K7/06 ,  A61K39/00

    CPC classification number: C07K4/12 ,  A61K31/7088 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0011 ,  A61K2039/572 ,  C07K7/06 ,  C07K14/47 ,  G01N2500/00

    Abstract: The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 19, 22, 30, 34, 344, 358, 41, 44, 46, 48, 78, 376, 379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117, 121, 395, 133, 135, 137, 426, 143, 147, 148, 149, 150, 152, 153, 154, 156, 160, 161, 162, 163, 166, 174, 178, 186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, 271, 272 or 288, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several (e.g., up to 5) amino acids are substituted, deleted, or added, provided the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with over-expression of the CDH3, EPHA4, ECT2, HIG2, INHBB, KIF20A, KNTC2, TTK and/or URLC10, e.g. cancers containing as an active ingredient one or more of these peptides. The peptides of the present invention find further utility as vaccines.

    Abstract translation: 本发明提供了具有SEQ ID NO：19,22,30,34,344,358,41,44,46,48,78,376,49,48,78,376,479,48和78的氨基酸序列的肽。 110,111,387,112,394,114,116,117,121,345,133,135,137,426,143,147,148,149,150,152,153,154,156,160,161， 162,163,166,174,178,186,194,196,202,210,213,214,217,223,227,228,233,254,271,272或288以及具有上述的肽的肽， 提供其中1,2或几个（例如，至多5个）氨基酸被取代，缺失或添加的上述氨基酸序列，条件是肽具有细胞毒性T细胞诱导性。 本发明还提供用于治疗或预防与CDH3，EPHA4，ECT2，HIG2，INHBB，KIF20A，KNTC2，TTK和/或URLC10的过表达相关的疾病的药物，例如。 含有这些肽中的一种或多种的活性成分的癌症。 本发明的肽可作为疫苗进一步发挥作用。

    EPITOPE PEPTIDES DERIVED FROM VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 AND VACCINES CONTAINING THESE PEPTIDES
    22.
    发明申请
    EPITOPE PEPTIDES DERIVED FROM VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 AND VACCINES CONTAINING THESE PEPTIDES 审中-公开
    从血管内皮生长因子受体1和含有这些肽的疫苗衍生的外源性肽

    公开(公告)号：US20140186381A1

    公开(公告)日：2014-07-03

    申请号：US14160436

    申请日：2014-01-21

    Applicant: Oncotherapy Science, Inc.

    Inventor： Hideaki Tahara ,  Takuya Tsunoda ,  Masabumi Shibuya ,  Shuichi Nakatsuru

    IPC: A61K39/00

    CPC classification number: A61K39/00 ,  A61K38/00 ,  C07K14/71

    Abstract: The present invention provides immunogenic peptides comprising the amino acid sequence of SEQ ID NO: 1, 2, 13, 32, and peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted or added, and having cytotoxic T cell inducibility, and also provides drugs for treating or preventing tumors comprising these peptides. The peptides of this invention can be used as vaccines.

    Abstract translation: 本发明提供了包含SEQ ID NO：1,23,32的氨基酸序列的免疫原性肽，以及包含其中1,2或几个氨基酸被取代或加入的上述氨基酸序列的肽，以及 具有细胞毒性T细胞诱导性，并且还提供用于治疗或预防包含这些肽的肿瘤的药物。 本发明的肽可用作疫苗。

    TOPK Peptides and Vaccines Including the Same
    25.
    发明申请
    TOPK Peptides and Vaccines Including the Same 有权
    TOPK肽和疫苗包括它

    公开(公告)号：US20160310586A1

    公开(公告)日：2016-10-27

    申请号：US15203103

    申请日：2016-07-06

    Applicant: OncoTherapy Science, Inc.

    Inventor： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe ,  Gaku Nakayama

    IPC: A61K39/00 ,  G01N33/50 ,  C12N9/12 ,  C07K16/40

    CPC classification number: A61K39/0011 ,  A61K38/00 ,  A61K39/0005 ,  A61K2039/5154 ,  A61K2039/572 ,  C07K7/06 ,  C07K14/4748 ,  C07K16/18 ,  C07K16/40 ,  C07K2317/34 ,  C12N9/12 ,  C12N9/1205 ,  C12Y207/12002 ,  G01N33/505 ,  G01N33/574

    Abstract: The present invention provides isolated epitope peptides derived from TOPK and immunogenic fragments thereof have an ability to induce cytotoxic T lymphocytes (CTLs) and thus are suitable for use in cancer immunotherapy, more particularly as cancer vaccines. The peptides of the present invention encompass both of peptides including a TOPK-derived amino acid sequence and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted and/or added, provided such modified versions have CTL inducibility. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, and pharmaceutical compositions of this invention find particular utility in either or both of the treatment and prevention of a number of cancers.

    Abstract translation: 本发明提供了源自TOPK的分离的表位肽，其免疫原性片段具有诱导细胞毒性T淋巴细胞（CTL）的能力，因此适用于癌症免疫治疗，更特别地，作为癌症疫苗。 本发明的肽包括包括TOPK衍生的氨基酸序列和其修饰形式的两种肽，其中一个，两个或几个氨基酸被取代，缺失，插入和/或添加，只要这些修饰版本具有CTL 诱导性。 还提供了编码任何前述肽的多核苷酸以及包括任何上述肽或多核苷酸的药物组合物。 本发明的肽，多核苷酸和药物组合物在治疗和预防多种癌症中的任一者或两者中都具有特别的用途。

    TOPK peptides and vaccines including the same
    26.
    发明授权
    TOPK peptides and vaccines including the same 有权
    TOPK肽和疫苗包括相同的

    公开(公告)号：US09427461B2

    公开(公告)日：2016-08-30

    申请号：US14353261

    申请日：2012-10-25

    Applicant: ONCOTHERAPY SCIENCE, INC.

    Inventor： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe ,  Gaku Nakayama

    IPC: A61K39/00 ,  C07K16/18 ,  C07K7/06 ,  G01N33/574 ,  C07K14/47 ,  G01N33/50 ,  C12N9/12 ,  A61K38/00

    CPC classification number: A61K39/0011 ,  A61K38/00 ,  A61K39/0005 ,  A61K2039/5154 ,  A61K2039/572 ,  C07K7/06 ,  C07K14/4748 ,  C07K16/18 ,  C07K16/40 ,  C07K2317/34 ,  C12N9/12 ,  C12N9/1205 ,  C12Y207/12002 ,  G01N33/505 ,  G01N33/574

    Abstract: The present invention provides isolated epitope peptides derived from TOPK and immunogenic fragments thereof have an ability to induce cytotoxic T lymphocytes (CTLs) and thus are suitable for use in cancer immunotherapy, more particularly as cancer vaccines. The peptides of the present invention encompass both of peptides including a TOPK-derived amino acid sequence and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted and/or added, provided such modified versions have CTL inducibility. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, and pharmaceutical compositions of this invention find particular utility in either or both of the treatment and prevention of a number of cancers.

    Abstract translation: 本发明提供了源自TOPK的分离的表位肽，其免疫原性片段具有诱导细胞毒性T淋巴细胞（CTL）的能力，因此适用于癌症免疫治疗，更特别地，作为癌症疫苗。 本发明的肽包括包括TOPK衍生的氨基酸序列和其修饰形式的两种肽，其中一个，两个或几个氨基酸被取代，缺失，插入和/或添加，只要这些修饰版本具有CTL 诱导性。 还提供了编码任何前述肽的多核苷酸以及包括任何上述肽或多核苷酸的药物组合物。 本发明的肽，多核苷酸和药物组合物在治疗和预防多种癌症中的任一者或两者中都具有特别的用途。

    FOXM1 peptide and medicinal agent comprising the same
    29.
    发明授权
    FOXM1 peptide and medicinal agent comprising the same 有权
    FOXM1肽及其药剂

    公开(公告)号：US09073968B2

    公开(公告)日：2015-07-07

    申请号：US14036879

    申请日：2013-09-25

    Applicant: ONCOTHERAPY SCIENCE, INC.

    Inventor： Yasuharu Nishimura ,  Kazunori Yokomine ,  Takuya Tsunoda ,  Yusuke Nakamura

    IPC: A61K38/00 ,  C07K7/08 ,  A61K39/00 ,  C12N5/0783

    CPC classification number: A61K39/0011 ,  A61K38/00 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/585 ,  C07K7/06 ,  C07K7/08 ,  C12N5/0636 ,  C12N5/0638 ,  C12N2501/998 ,  C12N2502/11

    Abstract: An objective of the present invention is to provide a means for enabling cancer immunotherapy that targets approximately 30% of various cancer patients that highly express forkhead box M1 (FOXM1) among the Japanese, by identifying FOXM1-derived peptides that can activate cancer cell-damaging human killer T cells by binding to HLA-A2. The present invention provides a peptide of (A) or (B) below: (A) a peptide including the amino acid sequence of any one of SEQ ID NOs: 1 to 3; (B) a peptide which includes the amino acid sequence of any one of SEQ ID NOs: 1 to 3, wherein one, two, or several amino acid(s) are substituted, deleted, inserted, and/or added, and wherein the peptide shows cytotoxic (killer) T cell-inducing activity.

    Abstract translation: 本发明的目的是提供一种能够通过鉴定可以激活癌细胞破坏性的FOXM1衍生的肽来靶向大约30％的高度表达日本人中的叉头盒M1（FOXM1）的各种癌症患者的癌症免疫治疗的手段 人类杀伤T细胞通过结合HLA-A2。 本发明提供下述（A）或（B）的肽：（A）包含SEQ ID NO：1〜3中任一项所述的氨基酸序列的肽; （B）包含SEQ ID NO：1至3中任一项的氨基酸序列的肽，其中一个，两个或几个氨基酸被取代，缺失，插入和/或添加，并且其中 肽显示出细胞毒性（杀伤）T细胞诱导活性。

    PEPTIDE VACCINES FOR CANCERS EXPRESSING TUMOR-ASSOCIATED ANTIGENS
    30.
    发明申请
    PEPTIDE VACCINES FOR CANCERS EXPRESSING TUMOR-ASSOCIATED ANTIGENS 审中-公开
    用于表达肿瘤相关抗原的癌症的肽疫苗

    公开(公告)号：US20140248300A1

    公开(公告)日：2014-09-04

    申请号：US14274373

    申请日：2014-05-09

    Applicant: OncoTherapy Science, Inc.

    Inventor： Takuya Tsunoda ,  Ryuji Ohsawa

    IPC: C07K4/12

    CPC classification number: C07K4/12 ,  A61K31/7088 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0011 ,  A61K2039/572 ,  C07K7/06 ,  C07K14/47 ,  G01N2500/00

    Abstract: The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 19, 22, 30, 34, 344, 358, 41, 44, 46, 48, 78, 376, 379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117, 121, 395, 133, 135, 137, 426, 143, 147, 148, 149, 150, 152, 153, 154, 156, 160, 161, 162, 163, 166, 174, 178, 186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, 271, 272 or 288, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several (e.g., up to 5) amino acids are substituted, deleted, or added, provided the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with over-expression of the CDH3, EPHA4, ECT2, HIG2, INHBB, KIF20A, KNTC2, TTK and/or URLC10, e.g. cancers containing as an active ingredient one or more of these peptides. The peptides of the present invention find further utility as vaccines.

    Abstract translation: 本发明提供了具有SEQ ID NO：19,22,30,34,344,358,41,44,46,48,78,376,49,48,78,376,479,48和78的氨基酸序列的肽。 110,111,387,112,394,114,116,117,121,345,133,135,137,426,143,147,148,149,150,152,153,154,156,160,161， 162,163,166,174,178,186,194,196,202,210,213,214,217,223,227,228,233,254,271,272或288以及具有上述的肽的肽， 提供其中1,2或几个（例如，至多5个）氨基酸被取代，缺失或添加的上述氨基酸序列，条件是肽具有细胞毒性T细胞诱导性。 本发明还提供用于治疗或预防与CDH3，EPHA4，ECT2，HIG2，INHBB，KIF20A，KNTC2，TTK和/或URLC10的过表达相关的疾病的药物，例如。 含有这些肽中的一种或多种的活性成分的癌症。 本发明的肽可作为疫苗进一步发挥作用。

Patent Agency Ranking